Aprea Therapeutics (NASDAQ:APRE) CFO Scott M. Coiante acquired 2,500 shares of Aprea Therapeutics stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average cost of $15.00 per share, with a total value of $37,500.00.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.